At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Prazosin +1 moredrug
Likely dose
Prazosin 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)
In Brief
A Phase 2 clinical trial evaluating Prazosin and Placebo oral capsule for Alzheimer's Disease and Disruptive Behavior. Completed, enrolled 35 participants across 14 sites.
Detailed Summary
The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Disruptive Behavior
CountriesUnited States
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartOct 2018
Primary CompletionJan 2022
TodayJul 2026
First PostedOct 18, 2018
Enrollment StartOct 23, 2018
Primary CompletionJan 5, 2022
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 7.7 years ago
Interventions
Prazosindrug
Oral prazosin HCl capsules (or placebo) will be administered twice daily, with individualized doses up to a maximum of 4 mg QAM mid-morning and 6 mg at bedtime (QHS), or matching placebo capsules
Placebo oral capsuledrug
Placebo capsule matched to appearance of active drug.